Baker & McKenzie acted for Canadian-based pharmaceutical company, Valeant Pharmaceuticals International, Inc. on its share subscription, via a private placement, of a 65% stake in Vietnam-based Euvipharm Pharmaceutical Joint-Stock Company. Valeant completed the acquisition in late July with a subscription price of above USD20 million.
Baker & McKenzie served as lead legal advisor to Valeant, from start to finish, including due diligence, negotiation, document drafting and licensing.
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products, primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
Euvipharm is a GMP-WHO certified full-service pharmaceutical manufacturer of Rx and OTC products for domestic and international markets. Valeant’s acquisition in Vietnam is representative of foreign investors’ increased interest in entering and operating in the country’s pharmaceutical and healthcare sector.
The Baker & McKenzie team primarily comprised of Partners Seck Yee Chung and Nguyen Lan Phuong, Associate Tran Duy Binh and Senior Regulatory Practitioner Vu Minh Ha.
Related Posts:
- None Found